Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential

Simple item page
dc.coverageDOI: 10.1016/j.jcyt.2020.04.089
dc.creatorKhoury, Maroun
dc.creatorRocco, Patricia R.M.
dc.creatorPhinney, Donald G.
dc.creatorKrampera, Mauro
dc.creatorMartin, Ivan
dc.creatorViswanathan, Sowmya
dc.creatorNolta, Jan A.
dc.creatorLeBlanc, Katarina
dc.creatorGalipeau, Jacques
dc.creatorWeiss, Daniel J.
dc.date2020
dc.date.accessioned2025-11-18T19:47:31Z
dc.date.available2025-11-18T19:47:31Z
dc.description<p>The serious consequences of the global coronavirus disease 2019 (COVID-19) pandemic have prompted a rapid global response to develop effective therapies that can lessen disease severity in infected patients. Cell-based approaches, primarily using mesenchymal stromal cells (MSCs), have demonstrated a strong safety profile and possible efficacy in patients with acute respiratory distress syndrome (ARDS), but whether these therapies are effective for treating respiratory virus-induced ARDS is unknown. According to the World Health Organization International Clinical Trials Registry Platform and the National Institutes of Health ClinicalTrials.gov databases, 27 clinical investigations of MSC-based cell therapy approaches have begun in China since the onset of the COVID-19 outbreak, with a growing number of academic and industry trials elsewhere as well. Several recent published reports have suggested potential efficacy; however, the available data presented are either anecdotal or from incomplete, poorly controlled investigations. Therefore, although there may be a potential role for MSCs and other cell-based therapies in treatment of COVID-19, these need to be investigated in a rationally designed, controlled approach if safety and efficacy are to be demonstrated accurately. The authors urge that the field proceed by finding a balance between swift experimentation and communication of results and scientifically coherent generation and analysis of clinical data.</p>eng
dc.descriptionThe serious consequences of the global coronavirus disease 2019 (COVID-19) pandemic have prompted a rapid global response to develop effective therapies that can lessen disease severity in infected patients. Cell-based approaches, primarily using mesenchymal stromal cells (MSCs), have demonstrated a strong safety profile and possible efficacy in patients with acute respiratory distress syndrome (ARDS), but whether these therapies are effective for treating respiratory virus-induced ARDS is unknown. According to the World Health Organization International Clinical Trials Registry Platform and the National Institutes of Health ClinicalTrials.gov databases, 27 clinical investigations of MSC-based cell therapy approaches have begun in China since the onset of the COVID-19 outbreak, with a growing number of academic and industry trials elsewhere as well. Several recent published reports have suggested potential efficacy; however, the available data presented are either anecdotal or from incomplete, poorly controlled investigations. Therefore, although there may be a potential role for MSCs and other cell-based therapies in treatment of COVID-19, these need to be investigated in a rationally designed, controlled approach if safety and efficacy are to be demonstrated accurately. The authors urge that the field proceed by finding a balance between swift experimentation and communication of results and scientifically coherent generation and analysis of clinical data.spa
dc.identifierhttps://investigadores.uandes.cl/en/publications/8e0b81de-3c5b-4a75-91e7-f926278eaa43
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/55086
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.22 (2020) nr.11 p.602-605
dc.subjectCOVID-19
dc.subjectMSCs
dc.subjectacute respiratory distress syndrome
dc.subjectcell therapy
dc.subjectcoronavirus
dc.subjectmesenchymal stromal cells
dc.subjectacute respiratory distress syndrome
dc.subjectcell therapy
dc.subjectcoronavirus
dc.subjectCOVID-19
dc.subjectmesenchymal stromal cells
dc.subjectMSCs
dc.subjectSDG 3 - Good Health and Well-being
dc.titleCell-based therapies for coronavirus disease 2019: proper clinical investigations are essentialeng
dc.typeReview articleeng
dc.typeArtículo de revisiónspa
Files
Collections
PURE